Prevention of glucocorticoid morbidity in giant cell arteritis

Frank Buttgereit, Eric Lawrence Matteson, Christian Dejaco, Bhaskar Dasgupta

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome by patients and rheumatologists include weight gain, psychological effects, osteoporosis, cardiometabolic complications and infections. The challenge is to maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment necessary to control GCA initially and then to prevent relapse but to give the minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the safety issues associated with long-term glucocorticoid use in patients with GCA and strategies for preventing glucocorticoid-related morbidity.

Original languageEnglish (US)
Pages (from-to)ii11-ii21
JournalRheumatology (United Kingdom)
Volume57
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Giant Cell Arteritis
Glucocorticoids
Morbidity
Osteoporosis
Therapeutics
Adrenal Insufficiency
Osteonecrosis
Infection
Hypercholesterolemia
Cataract
Weight Gain
Diabetes Mellitus
Odds Ratio
Psychology
Hypertension
Safety
Recurrence

Keywords

  • Adverse events
  • Giant cell arteritis
  • Glucocorticoids
  • Morbidity

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Prevention of glucocorticoid morbidity in giant cell arteritis. / Buttgereit, Frank; Matteson, Eric Lawrence; Dejaco, Christian; Dasgupta, Bhaskar.

In: Rheumatology (United Kingdom), Vol. 57, 01.02.2018, p. ii11-ii21.

Research output: Contribution to journalArticle

Buttgereit, Frank ; Matteson, Eric Lawrence ; Dejaco, Christian ; Dasgupta, Bhaskar. / Prevention of glucocorticoid morbidity in giant cell arteritis. In: Rheumatology (United Kingdom). 2018 ; Vol. 57. pp. ii11-ii21.
@article{7dd4228937c5405fb423ece176fd8f2a,
title = "Prevention of glucocorticoid morbidity in giant cell arteritis",
abstract = "Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome by patients and rheumatologists include weight gain, psychological effects, osteoporosis, cardiometabolic complications and infections. The challenge is to maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment necessary to control GCA initially and then to prevent relapse but to give the minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the safety issues associated with long-term glucocorticoid use in patients with GCA and strategies for preventing glucocorticoid-related morbidity.",
keywords = "Adverse events, Giant cell arteritis, Glucocorticoids, Morbidity",
author = "Frank Buttgereit and Matteson, {Eric Lawrence} and Christian Dejaco and Bhaskar Dasgupta",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/rheumatology/kex459",
language = "English (US)",
volume = "57",
pages = "ii11--ii21",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Prevention of glucocorticoid morbidity in giant cell arteritis

AU - Buttgereit, Frank

AU - Matteson, Eric Lawrence

AU - Dejaco, Christian

AU - Dasgupta, Bhaskar

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome by patients and rheumatologists include weight gain, psychological effects, osteoporosis, cardiometabolic complications and infections. The challenge is to maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment necessary to control GCA initially and then to prevent relapse but to give the minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the safety issues associated with long-term glucocorticoid use in patients with GCA and strategies for preventing glucocorticoid-related morbidity.

AB - Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome by patients and rheumatologists include weight gain, psychological effects, osteoporosis, cardiometabolic complications and infections. The challenge is to maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment necessary to control GCA initially and then to prevent relapse but to give the minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the safety issues associated with long-term glucocorticoid use in patients with GCA and strategies for preventing glucocorticoid-related morbidity.

KW - Adverse events

KW - Giant cell arteritis

KW - Glucocorticoids

KW - Morbidity

UR - http://www.scopus.com/inward/record.url?scp=85042609290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042609290&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kex459

DO - 10.1093/rheumatology/kex459

M3 - Article

C2 - 29982779

AN - SCOPUS:85042609290

VL - 57

SP - ii11-ii21

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

ER -